Dabur India (DABUR) Q4 03/04 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 03/04 earnings summary
23 Oct, 2026Executive summary
First full year as a focused FMCG business after the pharmaceutical demerger; revenue from operations rose 9.5% YoY to Rs 1,148 crore, while PAT rose 40.6% to Rs 101.2 crore.
Strategic execution centered on five core brands, new product launches, stronger distribution and operating efficiencies; new product launches generated the highest revenue in a single year.
Financial highlights
Revenue from operations was Rs 1,148 crore versus Rs 1,048.5 crore in 2002-03; total revenue was Rs 1,159 crore versus Rs 1,053.4 crore.
PBDIT rose 24.1% YoY to Rs 136.1 crore from Rs 109.6 crore; PAT rose 40.6% to Rs 101.2 crore from Rs 72 crore.
EPS increased to Rs 3.5 from Rs 2.5; interest outgo fell 42.2% to Rs 6.9 crore from Rs 11.9 crore.
Consolidated sales from operations increased 12% to Rs 1,329.6 crore; consolidated PAT after minority interest rose 36.7% to Rs 106.5 crore.
Outlook and guidance
Cautiously optimistic for 2004-05; adequate 2004 monsoon expected to support FMCG demand, while industry growth was expected to recover with a lag.
Plans emphasized rejuvenating existing products, launching new products, expanding exports and growing international operations’ share of sales and profits.
2004-05 priorities included streamlining food manufacturing and procurement, focused advertising, institutional sales and new product offerings.
Latest events from Dabur India
- Q2 revenue reached ₹3,563.07 crore; a ₹3.50 interim dividend was declared.DABUR
Q2 26/27 - Revenue and PAT advanced as exports and manufacturing capacity expanded.DABUR
Q4 96/97 - Core-brand focus and proposed portfolio exits underpin a Rs 2,000 crore FY03 target.DABUR
Q4 97/98 - Sales rose 13.5%; core growth offset restructuring costs and a slower FMCG market.DABUR
Q4 99/00 - Sales grew 12.7% as restructuring sharpened focus on core growth businesses.DABUR
Q4 98/99 - Flat sales, lower reported profit, and investment in global oncology growth.DABUR
Q4 01/02 - Sales outpaced a slow FMCG market as adjusted profit rose 39.2% and debt fell 32%.DABUR
Q4 00/01 - Profit rose 32.1% as efficiencies offset weak FMCG demand and restructuring advanced.DABUR
Q4 02/03 - FY05 delivered higher growth and margins; Balsara broadened the portfolio as input-cost risks persisted.DABUR
Q4 04/05